Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.30 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.30 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.30 |
| ▸ | KAT7 | O95251 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766896 | 0.84 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL1619666 | 0.79 | CNR2 (0.50) | CNR2CNR1 | |
| SCHEMBL12753875 | 0.76 | CNR2 (0.39) | CNR2CNR1KAT8 | |
| SCHEMBL13062811 | 0.74 | CNR2 (0.41) | CNR2 | |
| SCHEMBL1619502 | 0.73 | CNR2 (0.58) | CNR2 | |
| SCHEMBL4015146 | 0.73 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL12826891 | 0.72 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL1621077 | 0.72 | CNR2 (0.57) | CNR2 | |
| SCHEMBL10066902 | 0.72 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL14299985 | 0.72 | CNR2 (0.56) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329735-B2 | Tetrazole compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20120071529-A1 | Tetrazole Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071529-A1 | Tetrazole Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885GCK 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.